Management of the Idiopathic Overactive Bladder With Intradetrusor Injection of Type-A Botulinum Toxin: Systematic Review of the Literature
Overview
- Phase
- Not Applicable
- Intervention
- Intradetrusor Injection of Type-A Botulinum Toxin
- Conditions
- Urinary Bladder, Overactive
- Sponsor
- Clínica Infantil Colsubsidio
- Locations
- 1
- Primary Endpoint
- Efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence)
- Last Updated
- 13 years ago
Overview
Brief Summary
Overactive bladder is defined as a syndrome composed of urgency, increased urinary frequency, and sometimes urinary incontinence; its etiology may be characterized as neurogenic or non-neurogenic (i.e., idiopathic). This illness has a great impact in quality of life and one of the available treatments is the injection of Botulinum Toxin. This study aims to review the efficacy and safety of type-A Botulinum Toxin in the management of Idiopathic Overactive Bladder. A systematic search was performed in MEDLINE, EMBASE, CENTRAL and LILACS, and the controlled randomized clinical trials were chosen to review with the CONSORT criteria by independent reviewers. Outcomes analyzed were the efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence), adverse events to treatment, change in quality of life and urodynamic measures.
Investigators
Hugo Enrique López, MD
MD
Clínica Infantil Colsubsidio
Eligibility Criteria
Inclusion Criteria
- •Controlled randomized clinical trials
- •Adult patients diagnosed with idiopathic overactive bladder
- •Language of the study: english
Exclusion Criteria
- •Diagnosis of neurogenic overactive bladder
- •Patients under 18 years old
- •Use of Type-B Botulinum Toxin as the intervention
- •Other types of studies
Arms & Interventions
Intervention Group
Intervention: Intradetrusor Injection of Type-A Botulinum Toxin
Control Group
Intervention: Other interventions analyzed according to protocol
Outcomes
Primary Outcomes
Efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence)
Time Frame: Minimun follow-up period of 12 weeks
Secondary Outcomes
- Adverse events to treatment (urinary retention and urinary tract infections)(Minimun follow-up period of 12 weeks)
- Change in quality of life(Minimun follow-up period of 12 weeks)
- Change in urodynamic measures(Minimun follow-up period of 12 weeks)